Here are the 10-K annual reports from Liminatus Pharma, Inc. Warrants (LIMNW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LIMNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIMNW filings page.
Liminatus Pharma, Inc. reports full-year 2025 results as a pre-clinical cancer biotech focused on a next-generation CD47 immune checkpoint inhibitor for solid tumors such as non-small cell lung cancer. The company recorded a 2025 net loss of $10.2 million and had only $337,655 in cash at year-end, leading management to raise substantial doubt about its ability to continue as a going concern.
Liminatus had an accumulated deficit of $38.9 million and no revenue, reflecting its single-asset, late-preclinical status. In November 2025 and January 2026 it received multiple Nasdaq deficiency notices related to market value and minimum bid price requirements, creating listing risk. To bolster liquidity, in February 2026 it completed a best-efforts offering of common stock, pre-funded warrants, and common warrants at $0.29 per share, raising approximately $3.46 million net.